Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response

T Kalincik; A Manouchehrinia; L Sobisek; V Jokubaitis; T Spelman; D Horakova; E Havrdova; M Trojano; G Izquierdo; A Lugaresi; M Girard; A Prat; P Duquette; P Grammond; P Sola; R Hupperts; F Grand'Maison; E Pucci; C Boz; R Alroughani; V Van Pesch; J Lechner-Scott; M Terzi; R Bergamaschi; G Iuliano; F Granella; D Spitaleri; V Shaygannejad; C Oreja-Guevara; M Slee; R Ampapa; F Verheul; P McCombe; J Olascoaga; MP Amato; S Vucic; S Hodgkinson; C Ramo-Tello; S Flechter; E Cristiano; C Rozsa; F Moore; JL Sanchez-Menoyo; ML Saladino; M Barnett; J Hillert; H Butzkueven

Journal article

Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response

T Kalincik, A Manouchehrinia, L Sobisek, V Jokubaitis, T Spelman, D Horakova, E Havrdova, M Trojano, G Izquierdo, A Lugaresi, M Girard, A Prat, P Duquette, P Grammond, P Sola, R Hupperts, F Grand'Maison, E Pucci, C Boz, R Alroughani Show all

Brain | OXFORD UNIV PRESS | Published : 2017

DOI: 10.1093/brain/awx185

Download PDF

Abstract

Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response varies greatly among patients. Comprehensive predictive models of individual treatment response are lacking. Our aims were: (i) to develop predictive algorithms for individual treatment response using demographic, clinical and paraclinical predictors in patients with multiple sclerosis; and (ii) to evaluate accuracy, and internal and external validity of these algorithms. This study evaluated 27 demographic, clinical and paraclinical predictors of individual response to seven disease-modifying therapies in MSBase, a large global cohort study. Treatment response was a..

View full abstract

University of Melbourne Researchers

Tomas Kalincik Author

Timothy Spelman Author

Related Projects (5)

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

SELECTING OPTIMAL TREATMENT FOR PATIENTS WITH MULTIPLE SCLEROSIS

Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Clinical Centre of Research Excellence in Translational Neuroscience will provide people, pathways and resources to create a novel platform ..

Grants

Awarded by Bayer

Funding Acknowledgements

This study was financially supported by National Health and Medical Research Council (practitioner fellowship 1080518, project grants 1129189, 1083539 and 1032484 and centre for research excellence 1001216) and University of Melbourne (Faculty of Medicine, Dentistry and Health Sciences research fellowship). The MSBase Foundation is a not-for-profit organization that receives support from Biogen, Novartis, Merck, Roche, Teva and Sanofi Genzyme. The study was conducted separately and apart from the guidance of the sponsors.